Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study
CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are increasingly being used to define and stage Alzheimer's disease. These biomarkers can be measured more quickly and less invasively in plasma and may provide important information for early diagnosis of Alzhe...
Gespeichert in:
| Veröffentlicht in: | Brain (London, England : 1878) Jg. 143; H. 4; S. 1220 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
01.04.2020
|
| Schlagworte: | |
| ISSN: | 1460-2156, 1460-2156 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are increasingly being used to define and stage Alzheimer's disease. These biomarkers can be measured more quickly and less invasively in plasma and may provide important information for early diagnosis of Alzheimer's disease. We used stored plasma samples and clinical data obtained from 4444 non-demented participants in the Rotterdam study at baseline (between 2002 and 2005) and during follow-up until January 2016. Plasma concentrations of total-tau, NfL, amyloid-β40 and amyloid-β42 were measured using the Simoa NF-light® and N3PA assays. Associations between biomarker plasma levels and incident all-cause and Alzheimer's disease dementia during follow-up were assessed using Cox proportional-hazard regression models adjusted for age, sex, education, cardiovascular risk factors and APOE ε4 status. Moreover, biomarker plasma levels and rates of change over time of participants who developed Alzheimer's disease dementia during follow-up were compared with age and sex-matched dementia-free control subjects. During up to 14 years follow-up, 549 participants developed dementia, including 374 cases with Alzheimer's disease dementia. A log2 higher baseline amyloid-β42 plasma level was associated with a lower risk of developing all-cause or Alzheimer's disease dementia, adjusted hazard ratio (HR) 0.61 [95% confidence interval (CI), 0.47-0.78; P < 0.0001] and 0.59 (95% CI, 0.43-0.79; P = 0.0006), respectively. Conversely, a log2 higher baseline plasma NfL level was associated with a higher risk of all-cause dementia [adjusted HR 1.59 (95% CI, 1.38-1.83); P < 0.0001] or Alzheimer's disease [adjusted HR 1.50 (95% CI, 1.26-1.78); P < 0.0001]. Combining the lowest quartile group of amyloid-β42 with the highest of NfL resulted in a stronger association with all-cause dementia [adjusted HR 9.5 (95% CI, 2.3-40.4); P < 0.002] and with Alzheimer's disease [adjusted HR 15.7 (95% CI, 2.1-117.4); P < 0.0001], compared to the highest quartile group of amyloid-β42 and lowest of NfL. Total-tau and amyloid-β40 levels were not associated with all-cause or Alzheimer's disease dementia risk. Trajectory analyses of biomarkers revealed that mean NfL plasma levels increased 3.4 times faster in participants who developed Alzheimer's disease compared to those who remained dementia-free (P < 0.0001), plasma values for cases diverged from controls 9.6 years before Alzheimer's disease diagnosis. Amyloid-β42 levels began to decrease in Alzheimer's disease cases a few years before diagnosis, although the decline did not reach significance compared to dementia-free participants. In conclusion, our study shows that low amyloid-β42 and high NfL plasma levels are each independently and in combination strongly associated with risk of all-cause and Alzheimer's disease dementia. These data indicate that plasma NfL and amyloid-β42 levels can be used to assess the risk of developing dementia in a non-demented population. Plasma NfL levels, although not specific, may also be useful in monitoring progression of Alzheimer's disease dementia. |
|---|---|
| AbstractList | CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are increasingly being used to define and stage Alzheimer's disease. These biomarkers can be measured more quickly and less invasively in plasma and may provide important information for early diagnosis of Alzheimer's disease. We used stored plasma samples and clinical data obtained from 4444 non-demented participants in the Rotterdam study at baseline (between 2002 and 2005) and during follow-up until January 2016. Plasma concentrations of total-tau, NfL, amyloid-β40 and amyloid-β42 were measured using the Simoa NF-light® and N3PA assays. Associations between biomarker plasma levels and incident all-cause and Alzheimer's disease dementia during follow-up were assessed using Cox proportional-hazard regression models adjusted for age, sex, education, cardiovascular risk factors and APOE ε4 status. Moreover, biomarker plasma levels and rates of change over time of participants who developed Alzheimer's disease dementia during follow-up were compared with age and sex-matched dementia-free control subjects. During up to 14 years follow-up, 549 participants developed dementia, including 374 cases with Alzheimer's disease dementia. A log2 higher baseline amyloid-β42 plasma level was associated with a lower risk of developing all-cause or Alzheimer's disease dementia, adjusted hazard ratio (HR) 0.61 [95% confidence interval (CI), 0.47-0.78; P < 0.0001] and 0.59 (95% CI, 0.43-0.79; P = 0.0006), respectively. Conversely, a log2 higher baseline plasma NfL level was associated with a higher risk of all-cause dementia [adjusted HR 1.59 (95% CI, 1.38-1.83); P < 0.0001] or Alzheimer's disease [adjusted HR 1.50 (95% CI, 1.26-1.78); P < 0.0001]. Combining the lowest quartile group of amyloid-β42 with the highest of NfL resulted in a stronger association with all-cause dementia [adjusted HR 9.5 (95% CI, 2.3-40.4); P < 0.002] and with Alzheimer's disease [adjusted HR 15.7 (95% CI, 2.1-117.4); P < 0.0001], compared to the highest quartile group of amyloid-β42 and lowest of NfL. Total-tau and amyloid-β40 levels were not associated with all-cause or Alzheimer's disease dementia risk. Trajectory analyses of biomarkers revealed that mean NfL plasma levels increased 3.4 times faster in participants who developed Alzheimer's disease compared to those who remained dementia-free (P < 0.0001), plasma values for cases diverged from controls 9.6 years before Alzheimer's disease diagnosis. Amyloid-β42 levels began to decrease in Alzheimer's disease cases a few years before diagnosis, although the decline did not reach significance compared to dementia-free participants. In conclusion, our study shows that low amyloid-β42 and high NfL plasma levels are each independently and in combination strongly associated with risk of all-cause and Alzheimer's disease dementia. These data indicate that plasma NfL and amyloid-β42 levels can be used to assess the risk of developing dementia in a non-demented population. Plasma NfL levels, although not specific, may also be useful in monitoring progression of Alzheimer's disease dementia.CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are increasingly being used to define and stage Alzheimer's disease. These biomarkers can be measured more quickly and less invasively in plasma and may provide important information for early diagnosis of Alzheimer's disease. We used stored plasma samples and clinical data obtained from 4444 non-demented participants in the Rotterdam study at baseline (between 2002 and 2005) and during follow-up until January 2016. Plasma concentrations of total-tau, NfL, amyloid-β40 and amyloid-β42 were measured using the Simoa NF-light® and N3PA assays. Associations between biomarker plasma levels and incident all-cause and Alzheimer's disease dementia during follow-up were assessed using Cox proportional-hazard regression models adjusted for age, sex, education, cardiovascular risk factors and APOE ε4 status. Moreover, biomarker plasma levels and rates of change over time of participants who developed Alzheimer's disease dementia during follow-up were compared with age and sex-matched dementia-free control subjects. During up to 14 years follow-up, 549 participants developed dementia, including 374 cases with Alzheimer's disease dementia. A log2 higher baseline amyloid-β42 plasma level was associated with a lower risk of developing all-cause or Alzheimer's disease dementia, adjusted hazard ratio (HR) 0.61 [95% confidence interval (CI), 0.47-0.78; P < 0.0001] and 0.59 (95% CI, 0.43-0.79; P = 0.0006), respectively. Conversely, a log2 higher baseline plasma NfL level was associated with a higher risk of all-cause dementia [adjusted HR 1.59 (95% CI, 1.38-1.83); P < 0.0001] or Alzheimer's disease [adjusted HR 1.50 (95% CI, 1.26-1.78); P < 0.0001]. Combining the lowest quartile group of amyloid-β42 with the highest of NfL resulted in a stronger association with all-cause dementia [adjusted HR 9.5 (95% CI, 2.3-40.4); P < 0.002] and with Alzheimer's disease [adjusted HR 15.7 (95% CI, 2.1-117.4); P < 0.0001], compared to the highest quartile group of amyloid-β42 and lowest of NfL. Total-tau and amyloid-β40 levels were not associated with all-cause or Alzheimer's disease dementia risk. Trajectory analyses of biomarkers revealed that mean NfL plasma levels increased 3.4 times faster in participants who developed Alzheimer's disease compared to those who remained dementia-free (P < 0.0001), plasma values for cases diverged from controls 9.6 years before Alzheimer's disease diagnosis. Amyloid-β42 levels began to decrease in Alzheimer's disease cases a few years before diagnosis, although the decline did not reach significance compared to dementia-free participants. In conclusion, our study shows that low amyloid-β42 and high NfL plasma levels are each independently and in combination strongly associated with risk of all-cause and Alzheimer's disease dementia. These data indicate that plasma NfL and amyloid-β42 levels can be used to assess the risk of developing dementia in a non-demented population. Plasma NfL levels, although not specific, may also be useful in monitoring progression of Alzheimer's disease dementia. CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are increasingly being used to define and stage Alzheimer's disease. These biomarkers can be measured more quickly and less invasively in plasma and may provide important information for early diagnosis of Alzheimer's disease. We used stored plasma samples and clinical data obtained from 4444 non-demented participants in the Rotterdam study at baseline (between 2002 and 2005) and during follow-up until January 2016. Plasma concentrations of total-tau, NfL, amyloid-β40 and amyloid-β42 were measured using the Simoa NF-light® and N3PA assays. Associations between biomarker plasma levels and incident all-cause and Alzheimer's disease dementia during follow-up were assessed using Cox proportional-hazard regression models adjusted for age, sex, education, cardiovascular risk factors and APOE ε4 status. Moreover, biomarker plasma levels and rates of change over time of participants who developed Alzheimer's disease dementia during follow-up were compared with age and sex-matched dementia-free control subjects. During up to 14 years follow-up, 549 participants developed dementia, including 374 cases with Alzheimer's disease dementia. A log2 higher baseline amyloid-β42 plasma level was associated with a lower risk of developing all-cause or Alzheimer's disease dementia, adjusted hazard ratio (HR) 0.61 [95% confidence interval (CI), 0.47-0.78; P < 0.0001] and 0.59 (95% CI, 0.43-0.79; P = 0.0006), respectively. Conversely, a log2 higher baseline plasma NfL level was associated with a higher risk of all-cause dementia [adjusted HR 1.59 (95% CI, 1.38-1.83); P < 0.0001] or Alzheimer's disease [adjusted HR 1.50 (95% CI, 1.26-1.78); P < 0.0001]. Combining the lowest quartile group of amyloid-β42 with the highest of NfL resulted in a stronger association with all-cause dementia [adjusted HR 9.5 (95% CI, 2.3-40.4); P < 0.002] and with Alzheimer's disease [adjusted HR 15.7 (95% CI, 2.1-117.4); P < 0.0001], compared to the highest quartile group of amyloid-β42 and lowest of NfL. Total-tau and amyloid-β40 levels were not associated with all-cause or Alzheimer's disease dementia risk. Trajectory analyses of biomarkers revealed that mean NfL plasma levels increased 3.4 times faster in participants who developed Alzheimer's disease compared to those who remained dementia-free (P < 0.0001), plasma values for cases diverged from controls 9.6 years before Alzheimer's disease diagnosis. Amyloid-β42 levels began to decrease in Alzheimer's disease cases a few years before diagnosis, although the decline did not reach significance compared to dementia-free participants. In conclusion, our study shows that low amyloid-β42 and high NfL plasma levels are each independently and in combination strongly associated with risk of all-cause and Alzheimer's disease dementia. These data indicate that plasma NfL and amyloid-β42 levels can be used to assess the risk of developing dementia in a non-demented population. Plasma NfL levels, although not specific, may also be useful in monitoring progression of Alzheimer's disease dementia. |
| Author | de Wolf, Frank Waziry, Reem Gras, Luuk Ghanbari, Mohsen Kostense, Stefan Hofman, Albert Ikram, M Arfan Ikram, M Kamran McRae-McKee, Kevin Licher, Silvan Klap, Jaco Anderson, Roy Goudsmit, Jaap Koudstaal, Wouter Wermeling, Paulien Weverling, Gerrit Jan Sedaghat, Sanaz |
| Author_xml | – sequence: 1 givenname: Frank surname: de Wolf fullname: de Wolf, Frank organization: World Without Disease Accelerator, Data Science and Prevention Biomarkers, Johnson and Johnson, Leiden, The Netherlands – sequence: 2 givenname: Mohsen surname: Ghanbari fullname: Ghanbari, Mohsen organization: Department of Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran – sequence: 3 givenname: Silvan surname: Licher fullname: Licher, Silvan organization: Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands – sequence: 4 givenname: Kevin surname: McRae-McKee fullname: McRae-McKee, Kevin organization: Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, UK – sequence: 5 givenname: Luuk surname: Gras fullname: Gras, Luuk organization: World Without Disease Accelerator, Data Science and Prevention Biomarkers, Johnson and Johnson, Leiden, The Netherlands – sequence: 6 givenname: Gerrit Jan surname: Weverling fullname: Weverling, Gerrit Jan organization: World Without Disease Accelerator, Data Science and Prevention Biomarkers, Johnson and Johnson, Leiden, The Netherlands – sequence: 7 givenname: Paulien surname: Wermeling fullname: Wermeling, Paulien organization: World Without Disease Accelerator, Data Science and Prevention Biomarkers, Johnson and Johnson, Leiden, The Netherlands – sequence: 8 givenname: Sanaz surname: Sedaghat fullname: Sedaghat, Sanaz organization: Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA – sequence: 9 givenname: M Kamran surname: Ikram fullname: Ikram, M Kamran organization: Department of Neurology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands – sequence: 10 givenname: Reem surname: Waziry fullname: Waziry, Reem organization: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA – sequence: 11 givenname: Wouter surname: Koudstaal fullname: Koudstaal, Wouter organization: Lucidity Biomedical Consulting, Calle Emir 11, Granada, Spain – sequence: 12 givenname: Jaco surname: Klap fullname: Klap, Jaco organization: World Without Disease Accelerator, Data Science and Prevention Biomarkers, Johnson and Johnson, Leiden, The Netherlands – sequence: 13 givenname: Stefan surname: Kostense fullname: Kostense, Stefan organization: World Without Disease Accelerator, Data Science and Prevention Biomarkers, Johnson and Johnson, Leiden, The Netherlands – sequence: 14 givenname: Albert surname: Hofman fullname: Hofman, Albert organization: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA – sequence: 15 givenname: Roy surname: Anderson fullname: Anderson, Roy organization: Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, UK – sequence: 16 givenname: Jaap surname: Goudsmit fullname: Goudsmit, Jaap organization: Department of Immunology and infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA – sequence: 17 givenname: M Arfan surname: Ikram fullname: Ikram, M Arfan organization: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32206776$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtOwzAURC1URB-wZIu8ZEGoH6mdihWqeEmVYAHr6Ma-oQYnTuME1N_iQ_gmChSJ1YxGZ2YxYzKoQ42EHHN2ztlcTosWXD2FdwA2S_fIiKeKJYLP1OCfH5JxjC-M8VQKdUCGUgimtFYjsn7wECugHfRntMa-DaXzUGHdUe-eVx01q-0-hdpSqDY-OJt8flCPb-jjT9q6-EpDSS1-lxxcUKBNaHoPnQt1UkBES01Yhbajsevt5pDsl-AjHu10Qp6urx4Xt8ny_uZucblMjOS6S0wK3JTCKsQyK4oyy-bFzGZcI9fWMJkKyWGOWhgLMtUFMxpVWUptVKqBKTEhp7-7TRvWPcYur1w06D3UGPqYC5kJpbbn6C16skP7okKbN62roN3kfzeJL6o4buc |
| CitedBy_id | crossref_primary_10_3390_ijms22084128 crossref_primary_10_3233_JAD_201560 crossref_primary_10_3389_fnagi_2021_749649 crossref_primary_10_1177_13872877241309117 crossref_primary_10_1007_s11154_022_09728_7 crossref_primary_10_3233_JAD_200900 crossref_primary_10_3233_JAD_200901 crossref_primary_10_1111_pcn_13608 crossref_primary_10_1038_s41398_024_03049_w crossref_primary_10_4103_1673_5374_373681 crossref_primary_10_1038_s41572_021_00269_y crossref_primary_10_1212_WNL_0000000000200004 crossref_primary_10_3390_s24092829 crossref_primary_10_1016_j_bbih_2020_100185 crossref_primary_10_1039_D2NR05787E crossref_primary_10_1016_j_nbd_2024_106459 crossref_primary_10_1016_j_rceng_2024_07_002 crossref_primary_10_1002_alz_12614 crossref_primary_10_1002_alz_12613 crossref_primary_10_1093_jnci_djae113 crossref_primary_10_3233_JAD_221287 crossref_primary_10_1212_WNL_0000000000210271 crossref_primary_10_3390_ijms26052325 crossref_primary_10_1002_alz_12986 crossref_primary_10_1002_alz_13390 crossref_primary_10_1186_s13195_023_01377_5 crossref_primary_10_1016_j_jhazmat_2024_136719 crossref_primary_10_1016_j_aca_2024_342885 crossref_primary_10_3389_fnins_2022_804774 crossref_primary_10_1016_j_jfma_2024_01_018 crossref_primary_10_1002_dad2_12099 crossref_primary_10_1038_s41591_025_03605_x crossref_primary_10_1002_alz_13485 crossref_primary_10_1186_s12916_021_01915_8 crossref_primary_10_1016_j_neurobiolaging_2022_08_008 crossref_primary_10_3233_JAD_231080 crossref_primary_10_3233_JAD_210064 crossref_primary_10_1002_alz_13000 crossref_primary_10_1016_j_neurobiolaging_2022_10_004 crossref_primary_10_3389_fnagi_2022_1046066 crossref_primary_10_1007_s00401_020_02195_x crossref_primary_10_3389_fphar_2022_1015966 crossref_primary_10_3390_cells11091506 crossref_primary_10_1016_j_jchf_2022_09_006 crossref_primary_10_1212_WNL_0000000000208061 crossref_primary_10_1002_dad2_12405 crossref_primary_10_1093_sleep_zsaa272 crossref_primary_10_1186_s13024_023_00598_4 crossref_primary_10_1002_dad2_12409 crossref_primary_10_1002_smll_202503786 crossref_primary_10_1186_s13195_022_01143_z crossref_primary_10_1212_WNL_0000000000200035 crossref_primary_10_3233_JND_200623 crossref_primary_10_1186_s13195_023_01333_3 crossref_primary_10_3390_diagnostics12040796 crossref_primary_10_3389_fnagi_2022_896848 crossref_primary_10_1002_alz_13860 crossref_primary_10_1002_alz_12777 crossref_primary_10_1016_j_tjpad_2025_100186 crossref_primary_10_1080_02699052_2022_2037711 crossref_primary_10_1016_j_jstrokecerebrovasdis_2022_106568 crossref_primary_10_1002_acn3_51676 crossref_primary_10_1093_arclin_acae019 crossref_primary_10_1148_radiol_233019 crossref_primary_10_1007_s12035_021_02562_z crossref_primary_10_1038_s41467_020_19543_w crossref_primary_10_1007_s12035_020_02140_9 crossref_primary_10_1039_D3SC03981A crossref_primary_10_1186_s40035_021_00234_5 crossref_primary_10_15252_emmm_202114408 crossref_primary_10_1097_WAD_0000000000000579 crossref_primary_10_1227_neu_0000000000002010 crossref_primary_10_1093_jn_nxab381 crossref_primary_10_1097_CM9_0000000000002566 crossref_primary_10_3390_biomedicines10010169 crossref_primary_10_1038_s41398_022_02237_w crossref_primary_10_3389_fendo_2024_1375302 crossref_primary_10_3389_fnins_2023_1237284 crossref_primary_10_1016_j_tjpad_2025_100299 crossref_primary_10_1038_s43587_021_00070_2 crossref_primary_10_1080_14737175_2021_1965879 crossref_primary_10_1016_j_archger_2024_105703 crossref_primary_10_1016_j_bbi_2023_11_009 crossref_primary_10_1002_alz_12745 crossref_primary_10_3389_fneur_2021_691509 crossref_primary_10_1007_s10654_024_01131_7 crossref_primary_10_1021_acs_analchem_4c05421 crossref_primary_10_1038_s41598_021_95425_5 crossref_primary_10_1002_mds_28779 crossref_primary_10_1016_j_neuroimage_2020_117646 crossref_primary_10_1186_s13024_022_00523_1 crossref_primary_10_1002_alz_12997 crossref_primary_10_3233_JAD_231162 crossref_primary_10_1097_MNH_0000000000001117 crossref_primary_10_1186_s13195_021_00815_6 crossref_primary_10_2147_NDT_S267673 crossref_primary_10_1002_jbt_22953 crossref_primary_10_1038_s44184_024_00093_8 crossref_primary_10_3389_fnagi_2025_1547394 crossref_primary_10_3390_healthcare13050452 crossref_primary_10_3390_ijms26147026 crossref_primary_10_3389_fnagi_2022_930315 crossref_primary_10_1016_j_hrthm_2024_08_048 crossref_primary_10_3389_fphar_2024_1408462 crossref_primary_10_1007_s11357_023_00876_5 crossref_primary_10_1186_s13195_021_00841_4 crossref_primary_10_1002_trc2_12254 crossref_primary_10_1002_dad2_12564 crossref_primary_10_1097_YCO_0000000000000756 crossref_primary_10_1186_s13195_020_00697_0 crossref_primary_10_1016_j_csda_2022_107566 crossref_primary_10_3233_JAD_210496 crossref_primary_10_1159_000513008 crossref_primary_10_1186_s12883_024_03728_7 crossref_primary_10_1212_WNL_0000000000201289 crossref_primary_10_1177_13872877251361934 crossref_primary_10_3233_JAD_230604 crossref_primary_10_3390_medicina58030433 crossref_primary_10_1007_s11357_023_00888_1 crossref_primary_10_3389_fnins_2021_785276 crossref_primary_10_1186_s12979_023_00363_7 crossref_primary_10_1002_hbm_25151 crossref_primary_10_1038_s43856_025_01096_y crossref_primary_10_1002_alz_12212 crossref_primary_10_1186_s13195_020_00738_8 crossref_primary_10_1186_s13195_021_00902_8 crossref_primary_10_1002_alz_70328 crossref_primary_10_3389_fnins_2021_642384 crossref_primary_10_1038_s41380_024_02840_x crossref_primary_10_1136_jnnp_2020_325537 crossref_primary_10_3390_smartcities5020036 crossref_primary_10_1038_s43856_024_00713_6 crossref_primary_10_1093_brain_awac190 crossref_primary_10_1002_brb3_70775 crossref_primary_10_1007_s10162_021_00799_y crossref_primary_10_1080_19485565_2024_2334687 crossref_primary_10_3233_JAD_220591 crossref_primary_10_1111_cns_13962 crossref_primary_10_1002_brb3_2997 crossref_primary_10_3233_JAD_215562 crossref_primary_10_1002_alz_12466 crossref_primary_10_1016_j_diabres_2024_111790 crossref_primary_10_3233_JAD_200755 crossref_primary_10_1093_clinchem_hvab192 crossref_primary_10_3389_fneur_2021_805135 crossref_primary_10_1093_aje_kwad197 crossref_primary_10_1016_j_ebiom_2022_103980 crossref_primary_10_1016_j_rce_2024_06_008 crossref_primary_10_1111_pcn_13661 crossref_primary_10_1038_s41380_024_02524_6 crossref_primary_10_1007_s11011_021_00733_4 crossref_primary_10_1111_ene_16089 crossref_primary_10_30773_pi_2024_0094 crossref_primary_10_1186_s13195_024_01459_y crossref_primary_10_1001_jamanetworkopen_2022_3602 crossref_primary_10_1212_WNL_0000000000209307 crossref_primary_10_1111_coa_70035 crossref_primary_10_3390_biomedicines13020279 crossref_primary_10_3389_fnagi_2025_1532676 crossref_primary_10_3389_fneur_2022_871947 crossref_primary_10_1007_s10654_024_01145_1 crossref_primary_10_1212_WNL_0000000000013229 crossref_primary_10_3389_fnagi_2020_557005 crossref_primary_10_1002_alz_13652 crossref_primary_10_3390_ijms242417361 crossref_primary_10_1002_trc2_70008 crossref_primary_10_1007_s13346_025_01863_3 crossref_primary_10_2196_47486 crossref_primary_10_25259_GJMPBU_38_2024 crossref_primary_10_3389_fnagi_2021_725914 crossref_primary_10_1016_j_bbi_2024_05_031 crossref_primary_10_1136_bmjno_2020_000079 crossref_primary_10_1177_22143602241301636 crossref_primary_10_1002_brx2_70029 crossref_primary_10_3233_JAD_215093 crossref_primary_10_3390_diagnostics11050788 crossref_primary_10_1002_alz_12496 crossref_primary_10_1212_WNL_0000000000012482 crossref_primary_10_1002_dad2_12514 crossref_primary_10_1007_s00415_023_11739_6 crossref_primary_10_1038_s41380_025_03149_z crossref_primary_10_1097_WCO_0000000000001236 crossref_primary_10_3389_fnagi_2021_698571 crossref_primary_10_1002_dad2_12519 crossref_primary_10_1038_s41467_023_42596_6 crossref_primary_10_3390_jcm13030806 crossref_primary_10_3233_JAD_230932 crossref_primary_10_3390_cells11081367 crossref_primary_10_1002_alz_12933 crossref_primary_10_3233_JAD_201499 crossref_primary_10_1186_s12916_022_02425_x crossref_primary_10_1002_alz_13116 crossref_primary_10_1016_j_arr_2024_102566 crossref_primary_10_1016_j_brainres_2024_148812 crossref_primary_10_1159_000531208 crossref_primary_10_1016_j_arr_2021_101492 crossref_primary_10_1016_j_neurobiolaging_2023_04_013 crossref_primary_10_3390_ijms24098117 crossref_primary_10_1186_s13024_025_00819_y crossref_primary_10_1038_s41598_022_05772_0 crossref_primary_10_1038_s43587_023_00565_0 crossref_primary_10_1186_s13195_025_01831_6 crossref_primary_10_1002_dad2_12295 crossref_primary_10_1212_NXG_0000000000200053 crossref_primary_10_1212_WNL_0000000000210225 crossref_primary_10_1016_j_atherosclerosis_2022_03_025 crossref_primary_10_1177_13872877251372641 crossref_primary_10_1016_j_neurobiolaging_2021_12_013 crossref_primary_10_1038_s41598_022_05177_z crossref_primary_10_1186_s13195_021_00834_3 crossref_primary_10_1016_j_jagp_2024_03_004 crossref_primary_10_1007_s12264_022_00836_7 crossref_primary_10_1038_s41598_020_77830_4 crossref_primary_10_1186_s13195_021_00955_9 crossref_primary_10_2147_CIA_S357994 crossref_primary_10_1038_s41467_023_43575_7 crossref_primary_10_1080_14737159_2023_2289553 crossref_primary_10_1002_dad2_12285 crossref_primary_10_1002_alz_12248 crossref_primary_10_1016_j_ibneur_2025_01_004 crossref_primary_10_1016_j_arr_2023_102044 crossref_primary_10_1089_aid_2020_0218 crossref_primary_10_3389_fnagi_2022_820385 |
| ContentType | Journal Article |
| Copyright | The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. |
| Copyright_xml | – notice: The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. |
| DBID | NPM 7X8 |
| DOI | 10.1093/brain/awaa054 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2156 |
| ExternalDocumentID | 32206776 |
| Genre | Journal Article |
| GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 0R~ 1TH 23N 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAIMJ AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN AAWTL ABDFA ABEJV ABEUO ABGNP ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNHQ ABNKS ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFS ACIWK ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AELWJ AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM C45 CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EMOBN ENERS F5P F9B FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NLBLG NOMLY NOYVH NPM O9- OAUYM OAWHX OBOKY OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 RIG ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TLC TR2 VVN W8F WH7 WOQ X7H YAYTL YKOAZ YSK YXANX ZKX ~91 7X8 ABPQP ABUFD ABXZS ADNBA AEMQT AFYAG AHGBF AJBYB AJNCP ALXQX |
| ID | FETCH-LOGICAL-c317t-c4a1cf2d6eef8bbf889b5d817e17dc034231a9e72cda347b0c7e6ff37c647a062 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 254 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000541770600028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2156 |
| IngestDate | Sun Nov 09 13:49:11 EST 2025 Wed Feb 19 02:30:26 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | dementia plasma biomarkers Alzheimer’s disease Aβ42 NfL |
| Language | English |
| License | The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c317t-c4a1cf2d6eef8bbf889b5d817e17dc034231a9e72cda347b0c7e6ff37c647a062 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/brain/article-pdf/143/4/1220/33111043/awaa054.pdf |
| PMID | 32206776 |
| PQID | 2382661567 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2382661567 pubmed_primary_32206776 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-04-01 |
| PublicationDateYYYYMMDD | 2020-04-01 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Brain (London, England : 1878) |
| PublicationTitleAlternate | Brain |
| PublicationYear | 2020 |
| SSID | ssj0014326 |
| Score | 2.678245 |
| Snippet | CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are increasingly being used to define and stage Alzheimer's disease. These... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1220 |
| Title | Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32206776 https://www.proquest.com/docview/2382661567 |
| Volume | 143 |
| WOSCitedRecordID | wos000541770600028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvDo0mSz3U3wICIWLy09KPQWJvvAQpu0Tar_yx_ib3J3m9qTIHjJIRCybCYz883Mfh9CN8ADgIRZdBIlnDDBFcl43CZBBCzWsaBaZF5sQvR68WCQ9OuCW1mPVS59onfUqpCuRt6yocXFkjYX95MpcapRrrtaS2iso0ZkX-asWgxWXQQW0fp0UUBsaOM1x6YF8a3MCTC04AMgcEoAv2WXPsp0dv-7vj20U-eX-GFhEPtoTecHaKtbd9AP0bRv0-Ux4Armt9iTWZqhNQobevDI4XQs3-ySMeQKw9iC-aEiX5945EaLSn_XzaLjwmDl64pDuMOAJz8qYMRFRYWd7O6swp679gi9dp5eHp9JLbtApE0mKiIZhNJQxbU2cZaZOE6ytopDoUOhpKcMDCHRgkoFERNZIIXmxkRCciYg4PQYbeRFrk8RBqYicBCU6YBpTsFma9KoyHDQOtC0ia6Xm5las3a9Csh1MS_T1XY20cnii6STBf9Gan2Q473jZ394-hxtU4eQ_azNBWoY-1PrS7Qp36thObvy9mKvvX73G9sJzeI |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+tau%2C+neurofilament+light+chain+and+amyloid-%CE%B2+levels+and+risk+of+dementia%3B+a+population-based+cohort+study&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=de+Wolf%2C+Frank&rft.au=Ghanbari%2C+Mohsen&rft.au=Licher%2C+Silvan&rft.au=McRae-McKee%2C+Kevin&rft.date=2020-04-01&rft.issn=1460-2156&rft.eissn=1460-2156&rft.volume=143&rft.issue=4&rft.spage=1220&rft_id=info:doi/10.1093%2Fbrain%2Fawaa054&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2156&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2156&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2156&client=summon |